Navigation Links
Bayer HealthCare to Sponsor World Federation of Hemophilia Global Training Program and Donate Kogenate® FS, Antihemophilic Factor (Recombinant), Commercially Valued At More Than $7 Million
Date:4/28/2011

e development of high-titer inhibitors necessitating alternative treatments to AHF. The most common adverse events observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.  Kogenate® FS/KOGENATE® Bayer is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

For important risk and use information, please see the full Prescribing Information at www.kogenatefs.com/prescribing-information.jsp.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About the World Federation of Hemophilia (WFH)

The World Federation of Hemophilia is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and other inherited bleeding disorders.  Established in 1963, it is a global network of patient organizations in 118 countries and has official recognition from the World Health Organization. Vi
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... NEW YORK , May 24, 2013 In ... Takeover Rules and Rule 14e-1 of the United States Exchange ... levels its original offer for Elan Corporation (NYSE: ELN). ... Acquisition Limited ("Royalty Pharma") made an offer for the entire ... Elan Corporation, plc ("Elan") (the "Original Offer").  ...
(Date:5/24/2013)... and BOSTON , May 24, 2013 ... and development company, is pleased to announce that it has engaged ... augment the Company,s business development capabilities in Japan ... than 15 years of experience in business development, licensing and alliance ... Inc., Roche Pharma ( Japan ), Nippon Roche and ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... and SAN DIEGO, Nov. 12 Tobira Therapeutics, ... and product discovery for the treatment of life-threatening ... and results from two double-blind, placebo-controlled studies of ... studies, a single-ascending dose (SAD) study and the ...
... , BOTHELL, Wash., Nov. 11 ... ), a global leader in automated external defibrillator ( ... appointed Peter Kingma as senior vice president, effective immediately. ... Marver, president and chief executive officer, and oversees the ...
Cached Medicine Technology:Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 3Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 4Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 5
(Date:5/25/2013)... News) -- Animals make great companions for senior citizens, but ... car are far more likely to crash than those who ... new study included 2,000 licensed drivers aged 70 and older. ... often they drove with their pet in the car. ... risk was twice as high as among those who never ...
(Date:5/25/2013)... 2013 Studies from Johns Hopkins University ... excessive weight and their inability to get adequate sleep. ... weight can naturally relieve many symptoms. , Johns ... sleep quality was significantly associated with overall weight loss, ... dated November 6th, 2012, researchers monitored 77 participants ...
(Date:5/25/2013)... On May 20, 2013 the Sydney ... to discuss or plan for their eventual demise, but it ... released a Must-Do List to help people properly arrange for ... a personal fact sheet.” , While not a formal document, ... personal data. It may include a summary of assets, ...
(Date:5/25/2013)... New York,NY (PRWEB) May 25, 2013 ... SizeItUp officially declared the integration of the 2012 ... Lamborghini Aventador is the latest entrant in the list ... Designed intelligently, the vehicle is all set to thrill ... with vicious acceleration power and spectacular looks, the 2012 ...
(Date:5/25/2013)... Many orthodontists have thought about moving their ... cloud is. Most people would naturally assume that ... their cloud service and support would own and maintain ... selling, they'd be wrong. Cloud providers lease space ... facility that houses servers and related equipment to run ...
Breaking Medicine News(10 mins):Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2
... MADISON, N.J., Sept. 4 Quest Diagnostics Incorporated (NYSE: ... services, today announced that it was again selected to be part of ... and DJSI North America). The company is in its sixth year on ... American Index (since 2005). , , According to Sustainable ...
... strategies , FRIDAY, Sept. 4 (HealthDay News) -- ... United Kingdom and Australia rethink their efforts to combat ... healthy diets and exercise -- aren,t working. , In ... , Australian researchers followed more than 250 overweight and ...
... , WASHINGTON, Sept. 4 Nurses appear to be taking ... according to a survey released today by the Center for American Nurses ... The Nurse Investor Education Survey reveals that nurses may be ... needs. In fact, most nurses say they do not know what those ...
... , , NEW HAVEN, Conn., Sept. 4 ... discovery, development and commercialization of novel antibiotics for the treatment ... Kassberg has joined the company as Chief Business Officer. In ... development activities. , , Mr. Kassberg, age ...
... NEW YORK, Sept. 4 Delcath Systems, Inc. (Nasdaq: ... proprietary treatment method for primary and metastatic cancers to the ... Surgery for the University of Pittsburgh School of Medicine will ... Third Annual Conference on Saturday, September 5, 2009 in Milan, ...
... ... end-to-end payment solutions for merchants across all distribution channels, and ClaimLogic, a leader ... a partnership today that enables ClaimLogic to provide PCI-compliant credit card processing services ... ...
Cached Medicine News:Health News:Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index 2Health News:Nurses and Retirement Security: A Looming Crisis? 2Health News:Nurses and Retirement Security: A Looming Crisis? 3Health News:Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer 2Health News:Delcath Systems, Inc. to Present Poster at International Liver Cancer Association 2009 Annual Conference 2Health News:EPX and ClaimLogic Announce Credit Card Processing Partnership 2Health News:EPX and ClaimLogic Announce Credit Card Processing Partnership 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: